# US 2023/0117150 A1 · Fully orthogonal system for protein synthisis in bacterial cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0117150 A1
- Document ID: US20230117150A1
- Status: Published application
- Kind: A1
- Application number: 17/907,191
- Filed: 2021-03-24
- Published: 2023-04-20
- Earliest claimed: 2020-03-24
- Assignees: The Board of Trustees of the University of Illinois
- Applicants: Northwestern University; The Board of Trustees of the University of Illinois
- Inventors: Michael C. Jewett; Alexander S. Mankin; Nikolay Aleksashin
- Web page: https://patentgrep.com/patent/US20230117150A1

## CPC

- C12N 15/70: Vectors or expression systems specially adapted for E. coli
- C12P 21/02: having a known sequence of two or more amino acids, e.g. glutathione
- C12N 9/104: {Aminoacyltransferases (2.3.2)}
- C12N 9/14: Hydrolases (3)
- C12N 15/67: General methods for enhancing the expression
- C12Y 203/02012: Peptidyltransferase (2.3.2.12)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}
- C12Y: ENZYMES

## Abstract

Disclosed are engineered polynucleotides, engineered ribosomes comprising the engineered polynucleotides, engineered cells and systems comprising the engineered polynucleotides and ribosomes, and methods of making and using the engineered polynucleotides, engineered ribosomes, engineered cells and systems. The engineered polynucleotides, engineered ribosomes, and engineered cells may be utilized to prepare sequence defined polymers and to select for mutant ribosomes that are capable of incorporating non-canonical amino acids into a polymer.

## Claims

### Claim 1

An engineered cell comprising a first protein translation mechanism and a second protein translation mechanism,
a) the first protein translation mechanism comprising a first engineered ribosome, the first engineered ribosome comprising:
i) a small subunit comprising ribosomal RNA (rRNA) and protein;
ii) a large subunit comprising a ribosomal RNA (rRNA) and protein; and
iii) a linking moiety,
wherein the linking moiety comprises a polynucleotide sequence and tethers the rRNA of the small subunit with the rRNA of the large subunit;
b) the second protein translation mechanism comprising a second engineered ribosome, the second engineered ribosome comprising:
i) a small subunit comprising rRNA and protein; and
ii) a large subunit comprising rRNA and protein;
wherein the second engineered ribosome lacks a linking moiety between the large subunit and the small subunit; and
wherein the small subunit of the second engineered ribosome comprises a modified anti-Shine-Dalgarno sequence to permit translation of templates having complementary and/or cognate Shine-Dalgarno sequence different from endogenous cellular mRNAs of the cell, and/or

### Claim 2 (depends on 1)

The engineered cell of claim 1, wherein the first and the second protein translation mechanisms are capable of supporting translation of a sequence defined polymer.

### Claim 3 (depends on 1)

The engineered cell of claim 1, wherein the first protein translation mechanism is capable of supporting translation of native, endogenous RNAs.

### Claim 4 (depends on 1)

The engineered cell of claim 1, wherein the second protein translation mechanism is capable of supporting translation of non-native, exogenous RNAs.

### Claim 5 (depends on 1)

The engineered cell of claim 1, wherein the second engineered ribosome comprises one or more change-of-function mutations, wherein the change-of-function mutation is not at the anti-Shine Dalgarno sequence.

### Claim 6 (depends on 1)

The engineered cell of claim 1, wherein the small subunit of the second engineered ribosome comprises a modified anti-Shine-Dalgarno sequence selected from the group consisting of 3′-GGUGUU-5′, 3′-UGGUGU-5′, 3′-GGUGUC-5′, 3′-GUUUAG-5′, 3′-UGGAAU-5′, 3′GGAUCU-5′, 3′-UGGAUC-5′, 3′-UGGUAA-5′, and 3′-UGGAUC-5′.

### Claim 7 (depends on 1)

The engineered cell of claim 1, wherein the second engineered ribosome comprises a change-of-function mutation in one or more of:
a) peptidyl transferase center (PTC);
b) nascent peptide exit tunnel (NPET);
c) interaction site with elongation factors;
d) tRNA binding sites;
e) chaperone binding sites;
f) nascent chain modifying enzyme biding sites;
g) GTPase center.

### Claim 8 (depends on 1)

The engineered cell of claim 1, wherein the large subunit of the second engineered ribosome comprises a change-of-function mutations at one or more of the following residues of a 23S rRNA: G2061, C2452, U2585, G2251, G2252, A2057, A2058, C2611, A2062, A2503, U2609, G2454, and G2455.

### Claim 9 (depends on 1)

The engineered cell of claim 1, wherein the first, the second, or both the first and the second engineered ribosomes comprises an antibiotic resistance mutation.

### Claim 10 (depends on 1)

The engineered cell of claim 1, wherein the large subunit of the first engineered ribosome comprises a permuted variant or mutant of a 23 SrRNA and/or the small subunit comprises a permuted variant or mutant of a 16S rRNA.

### Claim 11 (depends on 1)

The engineered cell of claim 1, wherein the linking moiety covalently bonds a helix of the large subunit selected from the group consisting of helix 10, helix, 38, helix 42, helix, 54, helix 58, helix, 63, helix 78, helix, 101, to a helix of the small subunit selected from the group consisting of helix 11, helix, 26, helix 33, and helix 44.

### Claim 12 (depends on 1)

A method for preparing a sequence-defined polymer, the method comprising:
(a) providing one or more of:
(i) the cell of claim 1;
(ii) a cell-free extract derived from the cells of claim 1;
(iii) purified translation system derived from the cell of claim 1;
b) providing an mRNA encoding the sequence-defined polymer to the cell or the cell-free extract; and
c) translating the mRNA in the cell or cell-free extract to provide the sequence-defined polymer.

### Claim at position 13

13-14. (canceled)

### Claim 15 (depends on 12)

The method of claim 12, wherein the cell-free extract comprises an S150 extract prepared from mid- to late-exponential growth phase cell cultures or cultures having an OD600 or at least about 2.0, 2.5, or 3.0 at time of harvest.

### Claim 16 (depends on 12)

The method of claim 12, wherein the mRNA encoding the sequence-defined polymer comprise a modified Shine-Dalgarno sequence and the engineered ribosome of the second translation system comprises an anti-Shine-Dalgarno sequence complementary to the modified Shine-Dalgarno sequence of the mRNA.

### Claim at position 16

17-22. (canceled)

### Claim 23 (depends on 1)

One or more polynucleotides, the one or more polynucleotides encoding the rRNA of the engineered ribosome of a) the first protein translation mechanism and/or encoding the rRNA of the engineered ribosome of b) the second protein translation mechanism of the engineered cell of claim 1.

### Claim 24 (depends on 23)

The polynucleotide of claim 23, wherein the polynucleotide is a vector.

### Claim 25 (depends on 23)

The polynucleotide of claim 23, wherein the polynucleotide further comprises a gene to be expressed by the engineered ribosome.

### Claim at position 20

26-32. (canceled)

### Claim 33 (depends on 1, 23)

A method for preparing an engineered ribosome, the method comprising expressing the polynucleotide of claim 23 in a host cell, optionally wherein the host cell comprises an engineered cell of claim 1.

### Claim 34 (depends on 33)

The method of claim 33, the method further comprising subjecting the host cell to selection and selecting a host cell comprising a mutant ribosome.

### Claim 35 (depends on 34)

The method of claim 34, wherein the mutant comprises a mutation in one or more of:
a) peptidyl transferase center (PTC);
b) nascent peptide exit tunnel (NPET);
c) interaction site with elongation factors;
d) tRNA binding sites;
e) chaperone binding sites;
f) nascent chain modifying enzyme biding sites;
g) GTPase center;
h) interaction site with the translocon; and
i) interaction sites with the auxiliary proteins facilitating translation.

### Claim 36

(canceled)
